Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
Portfolio Pulse from Vandana Singh
ImmunityBio Inc (NASDAQ:IBRX) announced an exclusive global supply agreement with the Serum Institute of India for Bacillus Calmette-Guerin (BCG) to address shortages for its bladder cancer combination therapy with Anktiva. The FDA approved Anktiva plus BCG for certain bladder cancers in April. The deal includes the supply of standard BCG and a next-generation recombinant BCG for clinical trials and future indications. ImmunityBio's shares slightly declined following the announcement.
May 03, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck & Co Inc, as the only U.S. manufacturer of BCG, could face increased competition from ImmunityBio's partnership with the Serum Institute of India for BCG supply.
Merck & Co Inc, currently the sole manufacturer of BCG in the U.S., might experience increased competitive pressures following ImmunityBio's announcement of securing a global supply of BCG with the Serum Institute of India. This development could potentially disrupt Merck's dominance in the BCG market, especially if ImmunityBio's Anktiva and BCG combination therapy gains traction and regulatory approvals in more indications.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
ImmunityBio Inc announced a global supply deal with the Serum Institute of India for BCG, crucial for its bladder cancer therapy with Anktiva, despite a slight share price drop.
The partnership with the Serum Institute of India to secure a crucial supply of BCG for ImmunityBio's bladder cancer therapy represents a significant step forward in addressing treatment shortages and advancing clinical trials. Although the immediate market reaction saw a slight decrease in share price, the strategic importance of this deal for ImmunityBio's product pipeline and its potential impact on addressing a critical healthcare need could positively influence the stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100